Grandes branquiópodos (Crustacea: Branchiopoda: Anostraca, Notostraca) en la provincia de Málaga (España) (año hidrológico 2012/2013)

Grans branquiòpodes (Crustacea, Branchiopoda: Anostraca, Notostraca) a la província de Màlaga, Espanya (any hidrològic 2012/2013) S'enumeren les cites d'una campanya de mostratge de grans branquiòpodes portada a terme a la província de Màlaga (Andalusia, sud d'Espanya) que ha permès la detecció de cinc espècies (Branchipus cortesi, Chirocephalus diaphanus, Streptocephalus torvicornis, Triops mauritanicus aggr. i Phallocryptus spinosa) en 90 masses d'aigua mostrejades.Large branchiopods (Crustacea, Branchiopoda, Anostraca, Notostraca) from Málaga province, Spain (2012/2013 hydrological year) This paper presents the occurrence of the large branchiopods detected during a survey carried out in the province of Málaga (Andalusia, southern Spain). Five species (Branchipus cortesi, Chirocephalus diaphanus, Streptocephalus torvicornis, Triops mauritanicus aggr. and Phallocryptus spinosa) were recorded at 90 sampled wetlands.Se enumeran las citas de una campaña de muestreo de grandes branquiópodos realizada en la provincia de Málaga (Andalucía, sur de España) que ha permitido la detección de cinco especies (Branchipus cortesi, Chirocephalus diaphanus, Streptocephalus torvicornis, Triops mauritanicus aggr. y Phallocryptus spinosa) en 90 masas de agua muestreadas

Phase II study of oral fingolimod (FTY720) in multiple sclerosis : 3-year results

In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The objectives were to monitor the 36-month, interim efficacy and safety results of the ongoing extension of this study. In the extension (months 7-36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients continued at the same dose. During months 15-24, all patients receiving fingolimod 5.0 mg switched to 1.25 mg. Of the 250 patients who entered the extension study, 173 (69%) continued to month 36. Most patients were free from gadolinium-enhanced lesions (88-89%) or new T2 lesions (70-78%) at month 36. Patients receiving continuous fingolimod treatment had sustained low annualized relapse rates of 0.20-0.21, and 68-73% remained relapse-free at month 36. Over 36 months, nasopharyngitis (34%), headache (30%), fatigue (19%) and influenza (18%) were the most commonly reported adverse events. Pulmonary function remained stable and blood pressure was stable after an initial increase (3-5 mmHg) during the first 6 months of fingolimod treatment; serious adverse events included infections and skin cancer. The low MRI and clinical disease activity at 6 months were maintained at 36 months with fingolimod, which was generally well tolerated by most patients. The efficacy and safety of oral fingolimod are being further evaluated in a large phase III MS study programme

Patients awaiting surgery for neurosurgical diseases during the first wave of the COVID-19 pandemic in Spain: a multicentre cohort study.

The large number of infected patients requiring mechanical ventilation has led to the postponement of scheduled neurosurgical procedures during the first wave of the COVID-19 pandemic. The aims of this study were to investigate the factors that influence the decision to postpone scheduled neurosurgical procedures and to evaluate the effect of the restriction in scheduled surgery adopted to deal with the first outbreak of the COVID-19 pandemic in Spain on the outcome of patients awaiting surgery. This was an observational retrospective study. A tertiary-level multicentre study of neurosurgery activity between 1 March and 30 June 2020. A total of 680 patients awaiting any scheduled neurosurgical procedure were enrolled. 470 patients (69.1%) were awaiting surgery because of spine degenerative disease, 86 patients (12.6%) due to functional disorders, 58 patients (8.5%) due to brain or spine tumours, 25 patients (3.7%) due to cerebrospinal fluid (CSF) disorders and 17 patients (2.5%) due to cerebrovascular disease. The primary outcome was mortality due to any reason and any deterioration of the specific neurosurgical condition. Second, we analysed the rate of confirmed SARS-CoV-2 infection. More than one-quarter of patients experienced clinical or radiological deterioration. The rate of worsening was higher among patients with functional (39.5%) or CSF disorders (40%). Two patients died (0.4%) during the waiting period, both because of a concurrent disease. We performed a multivariate logistic regression analysis to determine independent covariates associated with maintaining the surgical indication. We found that community SARS-CoV-2 incidence (OR=1.011, p Patients awaiting neurosurgery experienced significant collateral damage even when they were considered for scheduled procedures